Profile Image
Robert C. Flanigan Photo
Robert C. Flanigan
Primary Department
Bladder Cancer
Kidney Cancer
Testicular Cancer
Kidney Transplant
Prostate Cancer
Cardinal Bernardin Cancer Center
Loyola Hospital
Loyola Outpatient Center
Loyola Outpatient Center
Medical School
Case Western Reserve University School of Medicine
University Hospitals of Cleveland/Case Western Reserve University, Urology
Patel, HD; Clark, JI; Flanigan, RCCytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma: Are There Any Favorable Risk Patients? The Journal of urology 2021 ;
Koehne, EL; Flanigan, RCRe: Active Surveillance for Men with Intermediate Risk Prostate Cancer. European urology 2021 ;
Harris, AA; Korpics, M; Sherwani, Z; Farooq, A; Baldea, KG; Flanigan, R; Harkenrider, MM; Solanki, AAPatient and physician reported toxicity with two-fraction definitive high-dose-rate prostate brachytherapy: the impact of implant interval. Journal of contemporary brachytherapy 2020 ;12(3)
Kim, K; Kong, A; Flanigan, RC; Quek, ML; Hollowell, CMP; Vidal, PP; Branch, J; Dean, LA; Macias, V; Kajadacsy-Balla, AA; Fitzgibbon, ML; Cintron, D; Liu, L; Freeman, VLPre-diagnostic carbohydrate intake and treatment failure after radical prostatectomy for early-stage prostate cancer. Cancer causes & control : CCC 2019 ;30(3)
Atieh, M; McIntire, PJ; Kilic, I; Picken, MM; Flanigan, RC; Barkan, GA; Pambuccian, SELipofuscin pigmentation (so called "melanosis") of the bladder. Diagnostic cytopathology 2019 ;47(9)
Flanigan, RCRe: Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. European urology 2019 ;75(5)
Kirshenbaum, EJ; Doshi, C; Dornbier, R; Blackwell, RH; Bajic, P; Gupta, GN; Gorbonos, A; Turk, TMT; Flanigan, RC; Baldea, KGSocioeconomic Disparities in the Acute Management of Stone Disease in the United States. Journal of Endourology 2019 ;33(2)
Solanki, AA; Mysz, ML; Patel, R; Surucu, M; Kang, H; Plypoo, A; Bajaj, A; Korpics, M; Martin, B; Hentz, C; Gupta, G; Farooq, A; Baldea, KG; Pawlowski, J; Roeske, J; Flanigan, R; Small, W; Harkenrider, MMTransitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions. Advances in radiation oncology 2018 ;4(1)
Li, B; Kirshenbaum, EJ; Blackwell, RH; Gange, WS; Saluk, J; Zapf, MAC; Kothari, AN; Flanigan, RC; Gupta, GNThirty-day hospital revisits after prostate brachytherapy: who is at risk? Prostate international 2018 ;7(2)
Kirshenbaum,E. J.; Blackwell,R. H.; Li,B.; Kothari,A. N.; Kuo,P. C.; Flanigan,R. C.; Gorbonos,A.; Gupta,G. N.Implications of postoperative pulmonary aspiration following major urologic surgery The Canadian journal of urology 2018 ;25(1):9186-9192
Saluk, JL; Blackwell, RH; Gange, WS; Zapf, MAC; Kothari, AN; Kuo, PC; Quek, ML; Flanigan, RC; Gupta, GNThe LACE Score as a Tool to Identify Radical Cystectomy Patients at Increased Risk of 90-Day Readmission and Mortality. Current urology 2018 ;12(1)
Blackwell, RH; Kothari, AN; Shah, A; Gang, W; Quek, ML; Luchette, FA; Flanigan, RC; Kuo, PC; Gupta, GNAdhesive Bowel Obstruction Following Urologic Surgery: Improved Outcomes with Early Intervention. Current urology 2018 ;11(4)
Kramer, H; Kuffel, G; Thomas-White, K; Wolfe, AJ; Vellanki, K; Leehey, DJ; Bansal, VK; Brubaker, L; Flanigan, R; Koval, J; Wadhwa, A; Zilliox, MJDiversity of the midstream urine microbiome in adults with chronic kidney disease. International Urology and Nephrology 2018 ;50(6)
Bajic, P; Joyce, CJ; Flanigan, RCSunitinib and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. The Journal of urology 2018 ;
Catalona,W. J.; Richie,J. P.; Ahmann,F. R.; Hudson,M. A.; Scardino,P. T.; Flanigan,R. C.; DeKernion,J. B.; Ratliff,T. L.; Kavoussi,L. R.; Dalkin,B. L.; Waters,W. B.; MacFarlane,M. T.; Southwick,P. C.Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men The Journal of urology 2017 ;197(2S):S200-S207
Blackwell,R. H.; Kirshenbaum,E. J.; Zapf,M. A. C.; Kothari,A. N.; Kuo,P. C.; Flanigan,R. C.; Gupta,G. N.Incidence of Adverse Contrast Reaction Following Nonintravenous Urinary Tract Imaging European urology focus 2017 ;3(1):89-93
Patel,M.; Vellanki,K.; Leehey,D. J.; Bansal,V. K.; Brubaker,L.; Flanigan,R.; Koval,J.; Wadhwa,A.; Balasubramanian,N.; Sandhu,J.; Kramer,H.Urinary incontinence and diuretic avoidance among adults with chronic kidney disease International Urology and Nephrology 2016 ; :
Greco,K. A.; Franzen,C. A.; Foreman,K. E.; Flanigan,R. C.; Kuo,P. C.; Gupta,G. N.PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes Urology 2016 ;91:241.e1-241.e7
Blackwell,R. H.; Barton,G. J.; Kothari,A. N.; Zapf,M. A.; Flanigan,R. C.; Kuo,P. C.; Gupta,G. N.Early Intervention during Acute Stone Admissions: Revealing "The Weekend Effect" in Urological Practice The Journal of urology 2016 ; :
Ellimoottil,C.; Vijan,S.; Flanigan,R. C.A primer on clinical trial design Urologic oncology 2015 ;33(3):116-121
Franzen,C. A.; Blackwell,R. H.; Todorovic,V.; Greco,K. A.; Foreman,K. E.; Flanigan,R. C.; Kuo,P. C.; Gupta,G. N.Urothelial cells undergo epithelial-to-mesenchymal transition after exposure to muscle invasive bladder cancer exosomes Oncogenesis 2015 ;4:e163
Blackwell,R. H.; Ellimoottil,C.; Bajic,P.; Kothari,A.; Zapf,M.; Kliethermes,S.; Flanigan,R. C.; Quek,M. L.; Kuo,P. C.; Gupta,G. N.New Onset Postoperative Atrial Fibrillation Predicts Long-Term Cardiovascular Events Following Radical Cystectomy The Journal of urology 2015 ;194(4):944-949
Franzen,C. A.; Blackwell,R. H.; Foreman,K. E.; Kuo,P. C.; Flanigan,R. C.; Gupta,G. N.Urinary Exosomes: The Potential for Biomarker Utility, Intercellular Signaling and Therapeutics in Urological Malignancy The Journal of urology 2015 ; :
Wang,L.; Mudaliar,K.; Mehta,V.; Barkan,G. A.; Quek,M. L.; Flanigan,R. C.; Picken,M. M.Seeking a standard for adequate pathologic lymph node staging in primary bladder carcinoma Virchows Archiv : an international journal of pathology 2014 ;464(5):595-602
Ellimoottil,C.; Greco,K. A.; Hart,S.; Patel,T.; Sheikh,M. M.; Turk,T. M.; Flanigan,R. C.New modalities for evaluation and surveillance of complex renal cysts The Journal of urology 2014 ;192(6):1604-1611
Greco,K. A.; Flanigan,R. C.; Quek,M. L.Acute acalculous cholecystitis after radical cystectomy: a report of two cases International journal of urology : official journal of the Japanese Urological Association 2013 ;20(4):453-454
Flanigan,R. C.Legends in urology The Canadian journal of urology 2013 ;20(6):6998-7000
Flanigan,R. C.; Polcari,A. J.; Shore,N. D.; Price,T. H.; Sims,R. B.; Maher,J. C.; Whitmore,J. B.; Corman,J. M.An Analysis of Leukapheresis and central venous catheter use in the randomized, placebo controlled, phase 3 IMPACT trial of Sipuleucel-T for metastatic castrate resistant prostate cancer The Journal of urology 2013 ;189(2):521-526
Hannick,J. H.; Flanigan,R. C.How to prepare and present scientific manuscripts in English International journal of urology : official journal of the Japanese Urological Association 2013 ;20(2):136-139
Rao,M. V.; Ellimoottil,C.; Sondej,T.; Flanigan,R. C.; Quek,M. L.Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer Urologic oncology 2013 ;31(6):857-861
Rao,M. V.; Quek,M. L.; Jayram,G.; Ellimoottil,C.; Sondej,T.; Hugen,C. M.; Flanigan,R. C.; Steinberg,G. D.Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in Patients with Previous Prostate Radiotherapy ISRN urology 2013 ;2013:405064
Mehta,V.; Mudaliar,K.; Ghai,R.; Quek,M. L.; Milner,J.; Flanigan,R. C.; Picken,M. M.Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat Archives of Pathology & Laboratory Medicine 2013 ;137(11):1584-1590
Mehta,V.; Rycyna,K.; Baesens,B. M.; Barkan,G. A.; Paner,G. P.; Flanigan,R. C.; Wojcik,E. M.; Venkataraman,G.Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6 INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2012 ;5(6):496-502
Mehta,V.; Mehrotra,S.; Flanigan,R. C.; Wojcik,E. M.; Venkataraman,G.Vanishing prostate cancer on radical prostatectomy (RP) in the PSA era: incidence and follow-up data from a cohort of 1,060 patients between 1998 and 2010 Virchows Archiv : an international journal of pathology 2011 ;459(1):115-116
Flanigan,R. C.; Polcari,A. J.; Hugen,C. M.Prognostic variables and nomograms for renal cell carcinoma International Journal of Urology 2011 ;18(1):20-31
Mulhall,J. P.; Parker,M.; Waters,B. W.; Flanigan,R. C.The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU international 2010 ;105(1):37-41
Hugen,C. M.; Polcari,A. J.; Fitzgerald,M. P.; Dauw,C.; Flanigan,R. C.; Quek,M. L.Risk factors for recurrence following radical cystectomy for pathologic node negative bladder cancer. Journal of surgical oncology 2010 ;102(4):334-337
Hugen,C. M.; Polcari,A. J.; Quek,M. L.; Garza,R. P.; Fitzgerald,M. P.; Flanigan,R. C.Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the Stephenson nomogram. World journal of urology 2010 ;28(6):741-744
Polcari,A. J.; Gorbonos,A.; Milner,J. E.; Flanigan,R. C.The role of cytoreductive nephrectomy in the era of molecular targeted therapy International Journal of Urology 2009 ;16(3):227-233
Polcari,A. J.; Hugen,C. M.; Sivarajan,G.; Woods,M. E.; Paner,G. P.; Flanigan,R. C.; Quek,M. L.Comparison of open and robot-assisted pelvic lymphadenectomy for prostate cancer. Journal of Endourology 2009 ;23(8):1313-1317
Muller,A.; Parker,M.; Waters,B. W.; Flanigan,R. C.; Mulhall,J. P.Penile rehabilitation following radical prostatectomy: predicting success The journal of sexual medicine 2009 ;6(10):2806-2812
Flanigan,R. C.; Polcari,A.Words of wisdom. Re: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. European urology 2009 ;55(4):990-991
Lara,P. N.,Jr; Tangen,C. M.; Conlon,S. J.; Flanigan,R. C.; Crawford,E. D.Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. Journal of Urology 2009 ;181(2):512-516
Quek,M. L.; Flanigan,R. C.The role of lymph node density in bladder cancer prognostication World journal of urology 2009 ;27(1):27-32
Venkataraman,G.; Rycyna,K.; Rabanser,A.; Heinze,G.; Baesens,B. M.; Ananthanarayanan,V.; Paner,G. P.; Barkan,G. A.; Flanigan,R. C.; Wojcik,E. M.Morphometric signature differences in nuclei of Gleason pattern 4 areas in Gleason 7 prostate cancer with differing primary grades on needle biopsy. Journal of Urology 2009 ;181(1):88-93
Masoom,S.; Venkataraman,G.; Jensen,J.; Flanigan,R. C.; Wojcik,E. M.Renal FNA-based typing of renal masses remains a useful adjunctive modality: evaluation of 31 renal masses with correlative histology. Cytopathology 2009 ;20(1):50-55
Tal,R.; Valenzuela,R.; Aviv,N.; Parker,M.; Waters,W. B.; Flanigan,R. C.; Mulhall,J. P.Persistent erectile dysfunction following radical prostatectomy: the association between nerve-sparing status and the prevalence and chronology of venous leak. Journal of Sexual Medicine 2009 ;6(10):2813-2819
Alvarez,A.; Venkataraman,G.; Quek,M.; Flanigan,R.; Wojcik,E.High incidence of aneuploidy in low grade urothelial carcinomas International Journal of Urology 2008 ;15(3):279-279
Picken,M. M.; Chyna,B.; Flanigan,R. C.; Lee,J. M.Analysis of chromosome 1p abnormalities in renal oncocytomas by loss of heterozygosity studies: correlation with conventional cytogenetics and fluorescence in situ hybridization. American Journal of Clinical Pathology 2008 ;129(3):377-382
Flanigan,R. C.; Howards,S. S.Maintenance of Certification: what is it and why is it happening. AUA Update Series 2008 ;27:
Fok,C. S.; Liu,L.; Venkataraman,G.; Barkan,G. A.; Flanigan,R. C.; Wojcik,E. M.; Quek,M. L.Urine cytology for surveillance of the remnant urothelium after radical cystectomy and urinary diversion Journal of Urology 2008 ;179(4 Supplement):249
Suzuki,H.; Flanigan,R. C.; Okuyama,A.Prostate specific antigen (PSA)-based screening. International Journal of Urology 2008 ;15(9):757-762
Garcia,J. G.; Picken,M. M.; Flanigan,R. C.The importance of histology and cytogenetics in decision making for renal cell carcinoma. World journal of urology 2008 ;26(2):155-160
Meyer,P. N.; Cao,Y.; Jacobson,K.; Krausz,T.; Flanigan,R. C.; Picken,M. M.Chromosome 1 analysis in chromophobe renal cell carcinomas with tissue microarray (TMA)-facilitated fluorescence in situ hybridization (FISH) demonstrates loss of 1p/1 which is also present in renal oncocytomas. Diagnostic Molecular Pathology 2008 ;17(3):141-144
Davis,C. M.; Rao,M. V.; Flanigan,R. C.; Quek,M. L.Renal cell carcinoma in two patients with crossed fused ectopic kidneys. Urologia internationalis 2008 ;81(3):370-372
Wood,C.; Srivastava,P.; Bukowski,R.; Lacombe,L.; Gorelov,A. I.; Gorelov,S.; Mulders,P.; Zielinski,H.; Hoos,A.; Teofilovici,F.; Isakov,L.; Flanigan,R. C.; Figlin,R.; Gupta,R.; Escudier,B.An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008 ;372(9633):145-154
Denberg,T. D.; Flanigan,R. C.; Kim,F. J.; Hoffman,R. M.; Steiner,J. F.Self-reported volume of radical prostatectomies among urologists in the USA. BJU international 2007 ;99(2):339-343
Meyer,P. N.; Clark,J. I.; Flanigan,R. C.; Picken,M. M.Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. American Journal of Clinical Pathology 2007 ;128(1):70-79
Kapur,U.; Antic,T.; Venkataraman,G.; Durazo-Arvizu,R. A.; Quek,M. M.; Flanigan,R. C.; Wojcik,E. M.Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: identification of predictive features using bootstrap method. Urology 2007 ;70(5):1028-1033
Freeman,V. L.; Flanigan,R. C.; Meydani,M.Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer. Cancer Causes & Control 2007 ;18(2):211-218
Flanigan,R. C.Renal tumors: the good, the bad, and the ugly International Journal of Urology 2007 ;14(7):575-580
Kositsawat,J.; Flanigan,R. C.; Meydani,M.; Choi,Y. K.; Freeman,V. L.The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer. Journal of Urology 2007 ;178(6):2391-2396
Venkataraman,G.; Heinze,G.; Holmes,E. W.; Ananthanarayanan,V.; Bostwick,D. G.; Paner,G. P.; Bradford-De La garza,C. M.; Brown,H. G.; Flanigan,R. C.; Wojcik,E. M.Identification of patients with low-risk for aneuploidy: comparative discriminatory models using linear and machine-learning classifiers in prostate cancer. Prostate 2007 ;67(14):1524-1536
Nagda,S. N.; Mohideen,N.; Lo,S. S.; Khan,U.; Dillehay,G.; Wagner,R.; Campbell,S.; Flanigan,R. C.Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. International journal of radiation oncology, biology, physics 2007 ;67(3):834-840
Paner,G. P.; Lindgren,V.; Jacobson,K.; Harrison,K.; Cao,Y.; Campbell,S. C.; Flanigan,R. C.; Picken,M. M.High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: cytogenetic and fluorescence in situ hybridization studies. Archives of Pathology & Laboratory Medicine 2007 ;131(1):81-85
Quek,M. L.; Basrawala,Z.; McClung,C.; Flanigan,R. C.Radical cystectomy with extended lymphadenectomy in the presence of a pelvic kidney. Urology 2006 ;68(3):672.e21-672.e22
Denberg,T. D.; Kim,F. J.; Flanigan,R. C.; Fairclough,D.; Beaty,B. L.; Steiner,J. F.; Hoffman,R. M.The influence of patient race and social vulnerability on urologist treatment recommendations in localized prostate carcinoma. Medical care 2006 ;44(12):1137-1141
Bargaje,A.; Venkataraman,G.; Flanigan,R. C.; Wojcik,E. M.; Ananthanarayanan,V.Utility of prostate biopsy morphometric sum optical density for identifying extraprostatic extension on subsequent prostatectomy. Analytical & Quantitative Cytology & Histology 2006 ;28(6):343-345
Flanigan,R. C.Subspecialty certification in urology: a US perspective. Nature Clinical Practice Urology 2006 ;3(10):509
Milner,J. E.; Voelzke,B. B.; Flanigan,R. C.; Sharma,S. K.; Perry,K. T.; Turk,T. M.Urothelial-cell carcinoma and solitary kidney: outcomes with renal-sparing management. Journal of Endourology 2006 ;20(10):800-807
Venkataraman,G.; Ananthanarayanan,V.; Paner,G. P.; He,R.; Masoom,S.; Sinacore,J.; Flanigan,R. C.; Wojcik,E. M.Morphometric sum optical density as a surrogate marker for ploidy status in prostate cancer: an analysis in 180 biopsies using logistic regression and binary recursive partitioning. Virchows Archiv 2006 ;449(3):302-307
Basrawala,Z.; Alimirah,F.; Xin,H.; Mohideen,N.; Campbell,S. C.; Flanigan,R. C.; Choubey,D.Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Oncogene 2006 ;25(19):2812-2817
Herzer,M.; Zakowski,S. G.; Flanigan,R. C.; Johnson,P.The relationship between threat appraisal and social constraints in cancer survivors and their spouses. Journal of Behavioral Medicine 2006 ;29(6):549-560
Mulhall,J.; Land,S.; Parker,M.; Waters,W. B.; Flanigan,R. C.The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. Journal of Sexual Medicine 2005 ;2(4):532-540
Van Veldhuizen,P. J.; Faulkner,J. R.; Lara,P. N.,Jr; Gumerlock,P. H.; Goodwin,J. W.; Dakhil,S. R.; Gross,H. M.; Flanigan,R. C.; Crawford,E. D.; Southwest Oncology GroupA phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109 CANCER CHEMOTHERAPY AND PHARMACOLOGY 2005 ;56(1):39-45
Kefer,J. C.; Voelzke,B. B.; Flanigan,R. C.; Wojcik,E. M.; Waters,W. B.; Campbell,S. C.Risk assessment for occult malignancy in the prostate before radical cystectomy. Urology 2005 ;66(6):1251-1255
Cao,Y.; Paner,G. P.; Perry,K. T.; Flanigan,R. C.; Campbell,S. C.; Picken,M. M.Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System. Archives of Pathology & Laboratory Medicine 2005 ;129(4):487-491
Malaeb,B. S.; Martin,D. J.; Littooy,F. N.; Lotan,Y.; Waters,W. B.; Flanigan,R. C.; Koeneman,K. S.The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. BJU international 2005 ;95(7):977-981
Flanigan,R. C.Does lymphadenectomy improve cancer-specific survival in patients with renal cell carcinoma?. Nature Clinical Practice Urology 2005 ;2(12):588-589
Flanigan,R. C.Debulking nephrectomy in metastatic renal cancer Clinical Cancer Research 2004 ;10(18 Pt 2):6335S-41S
Flanigan,R. C.; Mickisch,G.; Sylvester,R.; Tangen,C.; Van Poppel,H.; Crawford,E. D.Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis Journal of Urology 2004 ;171(3):1071-1076
Rubinas,T. C.; Flanigan,R. C.; Picken,M. M.Pathologic quiz case: renal mass in an otherwise healthy man. Epithelioid angiomyolipoma. Archives of Pathology & Laboratory Medicine 2004 ;128(1):e19-20
Zakowski,S. G.; Ramati,A.; Morton,C.; Johnson,P.; Flanigan,R. C.Written emotional disclosure buffers the effects of social constraints on distress among cancer patients. Health Psychology 2004 ;23(6):555-563
Freeman,V. L.; Meydani,M.; Hur,K.; Flanigan,R. C.Inverse association between prostatic polyunsaturated fatty acid and risk of locally advanced prostate carcinoma. Cancer 2004 ;101(12):2744-2754
Lindgren,V.; Paner,G. P.; Flanigan,R. C.; Clark,J. I.; Campbell,S. C.; Picken,M. M.Renal tumor with overlapping distal nephron morphology and karyotype. Archives of Pathology & Laboratory Medicine 2004 ;128(11):1274-1278
Lindgren,V.; Paner,G. P.; Omeroglu,A.; Campbell,S. C.; Waters,W. B.; Flanigan,R. C.; Picken,M. M.Cytogenetic analysis of a series of 13 renal oncocytomas. Journal of Urology 2004 ;171(2 Pt 1):602-604
Atkins,M. B.; Avigan,D. E.; Bukowski,R. M.; Childs,R. W.; Dutcher,J. P.; Eisen,T. G.; Figlin,R. A.; Finke,J. H.; Flanigan,R. C.; George,D. J.; Goldberg,S. N.; Gordon,M. S.; Iliopoulos,O.; Kaelin,W. G.,Jr; Linehan,W. M.; Lipton,A.; Motzer,R. J.; Novick,A. C.; Stadler,W. M.; Teh,B. T.; Yang,J. C.; King,L.Innovations and challenges in renal cancer: consensus statement from the first international conference Clinical Cancer Research 2004 ;10(18 Pt 2):6277S-81S
Quinn,A. M.; Flanigan,R. C.; Sienko,A.; Wojcik,E. M.Cytologic features of recurrent lymphoma involving the urinary bladder. Diagnostic cytopathology 2004 ;31(3):185-188
Barnas,J. L.; Pierpaoli,S.; Ladd,P.; Valenzuela,R.; Aviv,N.; Parker,M.; Waters,W. B.; Flanigan,R. C.; Mulhall,J. P.The prevalence and nature of orgasmic dysfunction after radical prostatectomy. BJU international 2004 ;94(4):603-605
Duan,X.; Bruneval,P.; Hammadeh,R.; Fresco,R.; Eble,J. N.; Clark,J. I.; Vigneswaran,W. T.; Flanigan,R. C.; Picken,M. M.Metastatic juxtaglomerular cell tumor in a 52-year-old man. American Journal of Surgical Pathology 2004 ;28(8):1098-1102
Eggener,S. E.; Rubenstein,J. N.; Smith,N. D.; Nadler,R. B.; Kontak,J.; Flanigan,R. C.; Waters,W. B.; Picken,M.; Campbell,S. C.Renal tumors in young adults Journal of Urology 2004 ;171(1):106-110
Yonover,P. M.; Sharma,S. K.; Flanigan,R. C.Role of nephrectomy in metastatic kidney cancer Cancer Treatment & Research 2003 ;116:119-135
Zakowski,S. G.; Harris,C.; Krueger,N.; Laubmeier,K. K.; Garrett,S.; Flanigan,R. C.; Johnson,P.Social barriers to emotional expression and their relations to distress in male and female cancer patients. British Journal of Health Psychology 2003 ;8(Pt 3):271-286
Flanigan,R. C.Cytoreductive nephrectomy in metastatic renal cancer Current urology reports 2003 ;4(1):36-40
Flanigan,R. C.Heat Shock Proteins: Biology and Potential Clinical Application. Kidney Cancer 2003 ;1(1):19-25
Flanigan,R. C.Radical retropubic prostatectomy - what works for me Contemporary Urology 2003 ;15(5):13-17
Flanigan,R. C.; Campbell,S. C.; Clark,J. I.; Picken,M. M.Metastatic renal cell carcinoma Current Treatment Options in Oncology 2003 ;4(5):385-390
Campbell,S. C.; Flanigan,R. C.; Clark,J. I.Nephrectomy in metastatic renal cell carcinoma Current Treatment Options in Oncology 2003 ;4(5):363-372
Unger,J. M.; LeBlanc,M.; Crowley,J. J.; Grossman,H. B.; Natale,R. B.; Wozniak,A. J.; Berenson,J. R.; List,A. F.; Peters,W. A.,3rd; Flanigan,R. C.; Macdonald,J. S.; Al-Sarraf,M.; Thompson,I. M.; Coltman,C. A.,JrEstimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture. Journal of Clinical Oncology 2003 ;21(23 Suppl):246s-252s
Gatenby,R. A.; Gawlinski,E. T.; Tangen,C. M.; Flanigan,R. C.; Crawford,E. D.The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. Cancer research 2002 ;62(18):5218-5222
Dogan,N.; Mohideen,N.; Glasgow,G. P.; Keys,K.; Flanigan,R. C.Effect of prostatic edema on CT-based postimplant dosimetry. International journal of radiation oncology, biology, physics 2002 ;53(2):483-489
Flanigan,R. C.; Yonover,P. M.; Campbell,S. C.Role of nephrectomy in metastatic renal cell carcinoma. AUA Update Series 2002 ;21(13):242-248
Pantuck,A. J.; Zisman,A.; Chao,D.; Dorey,F.; Flanigan,R. C.; DeKernion,J. B.; Figlin,R.; Belldegrun,A.Survival advantage of Interleukin-2 over Interferon Immunotherapy when combine with cytoreductive nephrectomy based on SWOP 8949-matched populations. Journal of Urology 2002 ;167(Suppl 1):166
Whitehead,R. P.; Lew,D.; Flanigan,R. C.; Weiss,G. R.; Roy,V.; Glode,M. L.; Dakhil,S. R.; Crawford,E. D.Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. Journal of Immunotherapy 2002 ;25(4):352-358
Mulhall,J. P.; Slovick,R.; Hotaling,J.; Aviv,N.; Valenzuela,R.; Waters,W. B.; Flanigan,R. C.Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. Journal of Urology 2002 ;167(3):1371-1375
Piper,N. Y.; Bishoff,J. T.; Magee,C.; Haffron,J. M.; Flanigan,R. C.; Mintiens,A.; Van Poppel,H. P.; Thompson,I. M.; Harmon,W. J.Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma?. Urology 2001 ;58(6):849-852
Mercader,M.; Bodner,B. K.; Moser,M. T.; Kwon,P. S.; Park,E. S.; Manecke,R. G.; Ellis,T. M.; Wojcik,E. M.; Yang,D.; Flanigan,R. C.; Waters,W. B.; Kast,W. M.; Kwon,E. D.T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 2001 ;98(25):14565-14570
Schroder,L. E.; Lew,D.; Flanigan,R. C.; Eisenberger,M. A.; Seay,T. E.; Hammond,N.; Needles,B. M.; Crawford,E. D.Phase II evaluation of suramin in advanced renal cell carcinoma. A Southwest Oncology Group study Urologic oncology 2001 ;6(4):145-148
Flanigan,R. C.; Salmon,S. E.; Blumenstein,B. A.; Bearman,S. I.; Roy,V.; McGrath,P. C.; Caton,J. R.,Jr; Munshi,N.; Crawford,E. D.Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. New England Journal of Medicine 2001 ;345(23):1655-1659
Flanigan,R. C.; Yonover,P. M.The role of radical nephrectomy in metastatic renal cell carcinoma Seminars in urologic oncology 2001 ;19(2):98-102
Flanigan,R. C.; Yonover,P. M.The role of resection for patients with renal carcinoma Current oncology reports 2001 ;3(5):424-432
Freeman,V. L.; Meydani,M.; Yong,S.; Pyle,J.; Durazo-Arvizu,R. A.; Liao,Y.; Flanigan,R. C.; Waters,W. B.Assessing the effect of fatty acids on prostate carcinogenesis in humans: does self-reported dietary intake rank prostatic exposure correctly?. American Journal of Clinical Nutrition 2001 ;73(4):815-820
Ellis,T. M.; Moser,M. T.; Le,P. T.; Flanigan,R. C.; Kwon,E. D.Alterations in peripheral B cells and B cell progenitors following androgen ablation in mice. International immunology 2001 ;13(4):553-558
Elias,L.; Lew,D.; Figlin,R. A.; Flanigan,R. C.; Thompson,M. E.; Triozzi,P. L.; Belt,R. J.; Wood,D. P.,Jr; Rivkin,S. E.; David,E.Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study Cancer 2000 ;89(3):597-603
Gao,X.; Mohideen,N.; Flanigan,R. C.; Waters,W. B.; Wojcik,E. M.; Leman,C. R.The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection. Journal of Urology 2000 ;164(6):1982-1986
Freeman,V. L.; Meydani,M.; Yong,S.; Pyle,J.; Flanigan,R. C.; Waters,W. B.; Wojcik,E. M.Prostatic levels of fatty acids and the histopathology of localized prostate cancer. Journal of Urology 2000 ;164(6):2168-2172
Flanigan,R. C.; DeLaurentis,D. A.; Waters,W. B.; Kunz,K.Bacillus Calmette-Guerin. Is monthly maintenance an option for transitional cell carcinoma of the bladder? Urologic oncology 2000 ;6(1):16-19
Yonover,P. M.; Flanigan,R. C.Should radical nephrectomy be performed in the face of surgically incurable disease? Current opinion in urology 2000 ;10(5):429-434
Bakhos,R.; Shankey,T. V.; Flanigan,R. C.; Fisher,S.; Wojcik,E. M.Comparative analysis of DNA flow cytometry and cytology of bladder washings: review of discordant cases. Diagnostic cytopathology 2000 ;22(2):65-69
Catalona,W. J.; Southwick,P. C.; Slawin,K. M.; Partin,A. W.; Brawer,M. K.; Flanigan,R. C.; Patel,A.; Richie,J. P.; Walsh,P. C.; Scardino,P. T.; Lange,P. H.; Gasior,G. H.; Loveland,K. G.; Bray,K. R.Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000 ;56(2):255-260
Pitale,S. U.; Sizemore,G. W.; Bakhos,R.; DeJong,S. A.; Flanigan,R. C.; Emanuele,N. V.Renal cell carcinoma with metastasis to the thyroid gland Urologic oncology 2000 ;5(4):173-175
Catalona,W. J.; Partin,A. W.; Slawin,K. M.; Naughton,C. K.; Brawer,M. K.; Flanigan,R. C.; Richie,J. P.; Patel,A.; Walsh,P. C.; Scardino,P. T.; Lange,P. H.; deKernion,J. B.; Southwick,P. C.; Loveland,K. G.; Parson,R. E.; Gasior,G. H.Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 2000 ;55(3):372-376
Hafron,J. M.; Flanigan,R. C.Primary localized amyloidosis of the ureter and bladder managed by ileal interposition. Techniques in urology 2000 ;6(1):50-52